Active, not recruitingPhase 2NCT05922904

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Studying Classic Hodgkin lymphoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Hun Lee, MD, MD
M.D. Anderson Cancer Center
Intervention
Brentuximab vedotin(drug)
Enrollment
25 enrolled
Eligibility
18 years · All sexes
Timeline
2023 – 2027

Study locations (1)

Collaborators

Merck Sharp & Dohme LLC · Seagen Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05922904 on ClinicalTrials.gov

Other trials for Classic Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Classic Hodgkin lymphoma →

← Back to all trials